A new gene therapy treatment has restored some sight in a handful of
blind patients suffering from Leber's congenital amaurosis, a syndrome in which, because of a broken or missing gene called RPE65, retinal photoreceptor cells malfunction and eventually die.
Not exact matches
That study reported that the first two
patients treated, both of them legally
blind, had
suffered no ill effects from the cells.
Within a week, the
patients had
suffered a range of side effects, including vision loss, detached retinas and hemorrhage, ultimately leaving them
blind.
A new study out today in Neurology, provides the first evidence that rigorous visual training restores rudimentary sight in
patients who went partially
blind after
suffering a stroke, while
patients who did not train continued to get progressively worse.
GenSight Biologics» pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics to help preserve or restore vision in
patients suffering from
blinding retinal diseases.
More and more newly
blind patients pour into the facility, which is now
suffering from overcrowding, malnourishment, and serious injuries that receive no medical attention, as the inhabitants are not allowed off the premises and no uninfected are allowed on.
Per the study,
patients who take fluoroquinolones have a five times greater chance of
suffering from potentially
blinding retinal detachment than those not taking this type of antibiotic.